Pfizer
- Home
- /
- Partners & Products
- /
- Vaccines
- /
- Pfizer
Who Is Pfizer?
Pfizer has played a critical role in healthcare for more than a century and now is helping to usher in a new era of vaccine development. As a global leader in pneumococcal disease prevention, Pfizer will continue to push the boundaries of innovation. Not only has Pfizer developed Trumenba, to prevent meningococcal group B disease, they are currently working on a vaccine for Staphylococcus aureus, the leading cause of hospital-acquired infections. The company is also well known for bringing Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) and Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) to market.
Where is Pfizer Located?
Pfizer Inc is an American multinational pharmaceutical and biotechnology corporation headquartered in Manhattan, New York City, USA.
Who is Pfizer Owned By?
The largest shareholders of Pfizer Inc are owned by institutional investors including The Vanguard Group, Inc., BlackRock Fund Advisors, SSgA Funds Management, Capital Research & Management Company, Wellington Management Co. LLP, Geode Capital Management LLC, and Charles Schwab Investment Management.
Pfizer Vaccines History
In 1849 cousins Charles Pfizer and Charles Erhart founded Charles Pfizer & Company in a red brick building in Brooklyn, NY.
Pfizer has a long history in vaccine research and development, including a pivotal role in the eradication of polio and smallpox. Through the development of innovative delivery systems and technologies (the term often used is “novel vaccines”), we’ve created innovations for preventing deadly bacterial infections like those caused by S. pneumoniae and N. meningitidis.
In 2020-2021 Pfizer leads the world in developing a vaccine and treatment in response to the COVID-19 pandemic and commits to lightspeed manufacturing to expand vaccine and treatment access to people around the world.
Pfizer’s Vaccine Research & Development program includes an ongoing focus on the prevention of pneumococcal disease. They’re also advancing vaccines for additional serious childhood, adolescent and adult infections, including meningococcal disease, influenza, Lyme disease, respiratory syncytial virus (RSV), and C difficile.
What is the Pfizer Vaccine Adherence in Kids (VAKs) Program?
Pediatric vaccination has demonstrated proven value in reducing the rate of vaccine-preventable diseases. However, improving vaccine adherence remains a challenge in pediatric health care delivery. Pfizer’s Vaccine Adherence in Kids (VAKs) program can help support vaccination and overall health care for your pediatric patients. The program includes a reminder recall program with a variety of outreach options that span multiple communication channels. Let Pfizer help you reach your patients with their Vaccine Adherence in Kids (VAKs) program.
What Vaccines Are Made By Pfizer?
Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is a vaccine approved for children 6 weeks through adults for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). See full prescribing information for specific indications and more.
Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) is a vaccine approved for the prevention of invasive disease caused by 20 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) in individuals 6 weeks and older.
Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) eligible for people 6 months of age or older. This COVID-19 vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
COVID-19 vaccines from BioNTech and Pfizer, which are based on BioNTech proprietary mRNA technology, were developed by both BioNTech and Pfizer.
PFIZER® is a registered trademark of Pfizer Inc.
TRUMENBA® (Meningococcal Group B Vaccine), is the first FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis group B. It is indicated for individuals 10 through 25 years of age. To learn more about Trumenba please visit here.
TRUMENBA® is a registered trademark of Wyeth LLC.
Pfizer Vaccines Ordering
If you do not have a direct account with Pfizer, you may download the form here – Pfizer Direct Account form. MPPG will need your new account number once one is provided to you from Pfizer.
MPPG members currently receive an incredible 19% discount on Trumenba® (Meningococcal Group B Vaccine) when ordered directly from Pfizer vaccines, https://primevaccines.pfizer.com .